A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Propranolol (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2018 Status changed from not yet recruiting to recruiting.
- 03 Jan 2018 New trial record
- 02 Jan 2018 Planned initiation date changed from 30 Dec 2017 to 1 Feb 2018.